Published February 1, 2026
| Version v2
Dataset
Open
Plasma Proteomic Biomarkers for Predicting Immunochemotherapy Outcomes in Advanced Gastric Adenocarcinoma
Authors/Creators
Description
Immune checkpoint inhibitors (ICIs) plus chemotherapy are standard first-line therapy for advanced gastric (GC) and gastroesophageal junction cancer (GEJC), yet predictive biomarkers remain limited. In this prospective single-center study, 31 patients with advanced GC/GEJC receiving PD-1 inhibitor plus chemotherapy were enrolled. Plasma samples were collected at baseline and every two cycles. Immune-related proteins were quantified using the Olink Target 96 Immuno-Oncology panel.
Files
Files
(234.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:02ce81ca4fe8f92e00abc4110d09e71f
|
80.7 kB | Download |
|
md5:e6cc7c081941297fc677f6b3e68ec05c
|
35.5 kB | Download |
|
md5:2aabc246e73b4e8d94679c8af9c59130
|
109.2 kB | Download |
|
md5:5b2b4eb8c87528b025b721d10533bd55
|
9.0 kB | Download |